Bristol-Myers Squibb Company

Bristol-Myers Squibb Beats on EPS, Stock Down 1.1%

Bristol-Myers Squibb reported a better-than-expected EPS, which indicates some positive performance in their operations. However, the stock fell by 1.1%, suggesting that investors may have been looking for more comprehensive revenue details or guidance. The lack of additional information from the earnings call may have contributed to the stock's decline.